**Abstract**

**Background:** Reliable biology indicators for stress reaction and psychopathology are valuable markers for both psychological research and clinical practice. Recently, the measurement of salivary alpha-amylase (sAA) was introduced as a non-invasive and more convenience protocol. Several studies showed the high sensitivity of sAA level in various mental disorders, unfortunately there still no data on how the level of sAA in naïve-drugs of schizophrenia patients.

**Objective:** To determine whether sAA level could be as potential biomarker for therapeutic response in schizophrenia patients.

**Methods:** Using the cohort study, we collected 30 samples that met the inclusion criteria and 30 normal control samples.sAA level and PANSS score were taken 5 times at baseline, 3 days after treatment of antipsychotics, 5 days after treatment, 7 days, and 14 days after treatment of antipsychotics.

**Results:** Schizophrenia patients showed significant higher sAA levels compared to normal control group. sAA levels showed significant decline in correlation with the improvement of PANSS score within 2 weeks of antipsychotics therapy.

**Conclusion:** The measurement of sAA levels can be used as potential biomarker of therapeutic response in schizophrenia patients.
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